Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NLWKV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD19B
|
|||||
| Synonyms |
SGN-CD19B
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
HBU12ec
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
talirine
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Diffuse large b-cell lymphoma |
1 Trials
|
||||||||
| Follicular lymphoma |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires measurable disease after ≥2 prior systemic therapies with ECOG 0-1 and adequate organ function, excluding patients with prior CD19-targeted therapy (unless CD19+ confirmed), active infections, allogeneic transplants, or recent anticancer treatments within 4 weeks (2 weeks if progressive disease).
|
||||
| Administration Dosage |
Given intravenously Day 1 of 28-day or 42-day cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02702141 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma | ||||
| Primary Endpoint |
The primary endpoints evaluate safety profiles including adverse event incidence and laboratory abnormalities monitored through 1 month post-treatment in relapsed/refractory patients.
|
||||
| Other Endpoint |
Secondary objectives assess pharmacokinetics (SGN-CD19B blood concentrations for 3 weeks), immunogenicity (antitherapeutic antibodies), and efficacy measures (objective response rate, progression-free survival up to 3 years) in this heavily pretreated population.
|
||||